<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140076" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vogt-Koyanagi-Harada Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stern</surname>
            <given-names>Ethan M.</given-names>
          </name>
          <aff>Tulane Internal Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nataneli</surname>
            <given-names>Nathaniel</given-names>
          </name>
          <aff>BronxCare Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ethan Stern declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nathaniel Nataneli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140076.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Vogt-Koyanagi-Harada disease (VKH) is a central nervous system condition that specifically affects vision and hearing. This activity describes the presentation, evaluation, and management of Vogt-Koyanagi-Harada disease. It also highlights the importance of early detection and treatment by an interprofessional team of this condition and a presentation of the complications of recurrent disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the known pathophysiology of Vogt-Koyanagi-Harada disease.</p></list-item><list-item><p>Summarize the stages of Vogt-Koyanagi-Harada disease and the clinical findings in each stage.</p></list-item><list-item><p>Outline the treatment modalities for Vogt-Koyanagi-Harada disease and the most recent data on outcomes.</p></list-item><list-item><p>Review the importance of early identification and proper treatment to prevent the ocular complications of this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140076&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140076">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140076.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Vogt-Koyanagi-Harada disease (VKH) is a central nervous system condition that specifically affects vision and hearing. Descriptions of this disease date back to the 12 century, but the disease is named after three 20 century physicians who described the collective manifestations of this disease. Alfred Vogt initially described bilateral iridocyclitis and eyebrow depigmentation in 1906, followed by Yoshizo Koyanagi&#x02019;s 1926 description of bilateral serous detachments in association with cerebrospinal fluid (CSF) pleocytosis. Einosuke Harada identified the integumentary symptoms of the condition shortly thereafter. The disease presents with signs and symptoms of a loss of immune tolerance to melanocytes within the meninges, eyes, skin, hair, and ears.<xref ref-type="bibr" rid="article-140076.r1">[1]</xref></p>
        <p>This relatively rare condition has a distinct phenotypic picture in both its early and late manifestations. Despite identifiable clinical findings, the pathophysiologic mechanisms behind VKH have been challenging to identify. Over the last few years, some of the genetic and immunologic facets of VKH have been elucidated due to recent technological advances. Ophthalmic complications from this condition are numerous, and early identification and treatment can reduce morbidity.<xref ref-type="bibr" rid="article-140076.r2">[2]</xref><xref ref-type="bibr" rid="article-140076.r3">[3]</xref></p>
        <p>VKH is primarily treated via medical therapy, but surgical options exist for complications of the disease, such as subretinal fibrosis, glaucoma, and cataracts. The prognosis is mainly dependent on what stage of the disease treatment is initiated but can range from quiescent with minimal symptoms to debilitating vision loss and pain.<xref ref-type="bibr" rid="article-140076.r4">[4]</xref></p>
      </sec>
      <sec id="article-140076.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of VKH is not firmly established, but current theories posit that patients develop T-cell mediated immunity against melanocytes following recovery from an inciting viral environmental factor.<xref ref-type="bibr" rid="article-140076.r5">[5]</xref> Cytomegalovirus and Epstein Barr virus have been implicated in the disease process, but no definitive link has been identified. VKH is thought to be caused by the loss of tolerance of melanocytes, leading to a non-necrotizing granulomatous inflammation in the eye, the inner ear, the skin, and hair.<xref ref-type="bibr" rid="article-140076.r6">[6]</xref></p>
        <p>Recent genetic studies have implicated the presence of human leukocyte antigen (HLA) cell surface markers HLA-DRB4, HLA-DRB1-04*05, and HLA-DRB-04*01, as well as non-HLA genes involving lymphocyte regulations in IL-12 production and IL17 production.<xref ref-type="bibr" rid="article-140076.r7">[7]</xref><xref ref-type="bibr" rid="article-140076.r8">[8]</xref> Downregulation of microRNA in the production of interleukins and changes in non-coding RNA may also play a role in this condition.<xref ref-type="bibr" rid="article-140076.r8">[8]</xref><xref ref-type="bibr" rid="article-140076.r9">[9]</xref></p>
      </sec>
      <sec id="article-140076.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>There are regional differences in the prevalence of VKH among patients presenting with uveitis &#x02013; it is the most common cause of uveitis in India (prevalence 21.08%) and the second most common in Thailand. In the United States, VKH is a relatively rare cause of uveitis, representing only 3 to 4% of referrals to tertiary care centers.<xref ref-type="bibr" rid="article-140076.r10">[10]</xref>&#x000a0;Comparatively, roughly 800 new cases of VKH develop each year in Japan.<xref ref-type="bibr" rid="article-140076.r4">[4]</xref><xref ref-type="bibr" rid="article-140076.r10">[10]</xref>&#x000a0;Hispanic and Native American predominance has been noted in North American cases of VKH. Still, countries in South America with significant native and Hispanic populations, like Colombia, have not shown a significant increase in the incidence of VKH compared with the United States.<xref ref-type="bibr" rid="article-140076.r11">[11]</xref><xref ref-type="bibr" rid="article-140076.r12">[12]</xref>&#x000a0;</p>
        <p>Genetic studies may explain the difference in prevalence, as the DRB1-04*01 allele is more prevalent in East Asian populations and that HLA-DRB4 and HLA-DRB1 alleles are more correlated to the presence of VKH disease in affected populations.<xref ref-type="bibr" rid="article-140076.r8">[8]</xref>&#x000a0;Twin studies showed monozygotic twins developed VKH simultaneously, and twin and sibling studies have further confirmed that there is a genetic component to VKH.<xref ref-type="bibr" rid="article-140076.r13">[13]</xref><xref ref-type="bibr" rid="article-140076.r14">[14]</xref><xref ref-type="bibr" rid="article-140076.r15">[15]</xref></p>
        <p>Patients diagnosed with VKH are typically in the third or fourth decade of life (range: 3 years old to 78 years old).<xref ref-type="bibr" rid="article-140076.r16">[16]</xref><xref ref-type="bibr" rid="article-140076.r17">[17]</xref><xref ref-type="bibr" rid="article-140076.r18">[18]</xref>&#x000a0;Pediatric cases of VKH are often aggressive, long-standing, and challenging to treat and are more commonly associated with subretinal fibrosis.<xref ref-type="bibr" rid="article-140076.r19">[19]</xref>&#x000a0;Older patients, typically above the age of 65, have a higher propensity to develop optic disc hyperemia and choroidal detachments.<xref ref-type="bibr" rid="article-140076.r20">[20]</xref>&#x000a0;Women are more commonly affected than men, with ratios ranging from 3&#x000a0;to 2 to 2&#x000a0;to 1.<xref ref-type="bibr" rid="article-140076.r7">[7]</xref></p>
      </sec>
      <sec id="article-140076.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>As a response to an environmental factor, Th1 mediated inflammation develops against melanocytes. Tyrosinase peptide is a known target of T-cells, specifically in melanocytes expressing HLA DRB1-04*05.<xref ref-type="bibr" rid="article-140076.r21">[21]</xref><xref ref-type="bibr" rid="article-140076.r22">[22]</xref>&#x000a0;Comparing the tyrosinase peptide and a cytomegalovirus peptide has shown that homology exists between the two proteins. Other studies have shown EBV DNA by PCR in CSF of patients with VKH.<xref ref-type="bibr" rid="article-140076.r21">[21]</xref><xref ref-type="bibr" rid="article-140076.r23">[23]</xref>&#x000a0;</p>
        <p>This inflammatory cascade leads to the formation of non-necrotizing granulomas in affected organs. In the eye, these are seen as sub-retinal pigment epithelial (RPE) aggregates named Dalen-Fuchs nodules, which may also be seen in other granulomatous processes, especially sympathetic ophthalmia.</p>
      </sec>
      <sec id="article-140076.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology of&#x000a0;Dalen-Fuchs nodules shows granulomas consisting of epithelioid histiocytes. Hematoxylin and eosin staining of enucleated specimens show B-cells and T-cells in choroid and loss of choroidal melanocytes.<xref ref-type="bibr" rid="article-140076.r24">[24]</xref></p>
        <p>Recurrent episodes lead to an appearance known as a sunset-glow fundus, defined by progressive fundus depigmentation in the setting of optic disc pallor &#x02013; a marker of poor visual outcome in these patients. In the late stage of VKH, peripheral fundus scars are seen histopathologically as chorioretinal atrophy and scarring; Dalen-Fuchs nodules are not common in this stage.<xref ref-type="bibr" rid="article-140076.r24">[24]</xref><xref ref-type="bibr" rid="article-140076.r25">[25]</xref><xref ref-type="bibr" rid="article-140076.r26">[26]</xref></p>
      </sec>
      <sec id="article-140076.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>There are four specific phases of VKH &#x02013; prodromal, acute uveitic, chronic uveitic, and recurrent chronic phase.&#x000a0;</p>
        <p>The prodromal phase is often self-limited, lasts for hours to weeks, and has very subtle chorioretinal findings that are missed unless evaluated with ICG-angiography and correlated with cerebrospinal fluid analysis.<xref ref-type="bibr" rid="article-140076.r27">[27]</xref><xref ref-type="bibr" rid="article-140076.r28">[28]</xref>&#x000a0;Patients presenting during the prodromal phase of the disease will describe dizziness, eye pain, photophobia, headache, meningeal signs, or fever. A detailed history will often reveal that patients have recovered from a relatively recent viral illness.<xref ref-type="bibr" rid="article-140076.r24">[24]</xref></p>
        <p>The acute uveitic phase consists of blurry vision and photophobia secondary to chorioretinal inflammation. Edema secondary to inflammation in this stage can extend to the retina, the optic nerve, or the ciliary body leading to the development of exudative retinal detachments, papillitis, and acute anatomic angle closure, respectively.</p>
        <p>The chronic phase of the disease develops subsequently. This phase represents the formation of extraocular physical manifestations, including hearing manifestations, skin depigmentation, and ciliary depigmentation - commonly noted at the eyebrows, eyelashes, and scalp. Hearing manifestations include tinnitus, dysacusis, and hearing loss.<xref ref-type="bibr" rid="article-140076.r27">[27]</xref><xref ref-type="bibr" rid="article-140076.r28">[28]</xref><xref ref-type="bibr" rid="article-140076.r29">[29]</xref>&#x000a0;</p>
        <p>The recurrent chronic phase consists of symptoms of panuveitis, inflammation throughout the intraocular compartments, and subsequent vision-threatening signs such as sunset glow fundus, choroidal neovascular membranes, neovascularization of the iris, open- and closed-angle glaucoma, and subretinal fibrosis.</p>
        <p>The VKH International Workshop has defined the three classifications of VKH disease: complete VKH disease, incomplete VKH disease, and suspected VKH disease. Complete disease indicates that both neurologic and dermatologic manifestations are present in addition to ocular disease findings. The incomplete disease presents with either dermatologic symptoms or neurologic manifestations of VKH. Suspected VKH disease presents with intraocular findings without evidence of dermatologic or neurologic manifestations. All classifications of VKH require the exclusion of other causes of intraocular findings, including a history of penetrating trauma, surgery, or infectious etiologies.</p>
      </sec>
      <sec id="article-140076.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>VKH is a clinical diagnosis that requires a constellation of symptoms that can be supported with further laboratory and imaging evaluation. Patients undergo a complete history, focusing on the possible number of earlier episodes, meningeal symptoms, a history of eye or orbital pain, and hearing issues. Physical and slit lamp exams can reveal evidence of prior episodes because poliosis or vitiligo indicates that the patient has progressed through the chronic uveitic phase of the disease.</p>
        <p>Cerebrospinal fluid testing during the prodromal phase of VKH has shown pleocytosis, which can persist for several weeks after the resolution of symptoms.<xref ref-type="bibr" rid="article-140076.r27">[27]</xref>&#x000a0;There are no established serum tests for VKH. Still, one study of patients admitted for initiation of treatment with steroids in the acute uveitic phase of VKH found that the presence of elevated serum IgE was associated with increased vascular leakage and active inflammation.<xref ref-type="bibr" rid="article-140076.r30">[30]</xref>&#x000a0;Further studies need to be done to find other serologic markers for this condition.</p>
        <p>Indocyanine green angiography (ICGA), and to a lesser extent fluorescein angiography (FA), is established as the most important test for assessing VKH. ICGA can be used for diagnostic purposes but is also highly valuable for monitoring disease processes and responses to treatment.<xref ref-type="bibr" rid="article-140076.r27">[27]</xref><xref ref-type="bibr" rid="article-140076.r28">[28]</xref><xref ref-type="bibr" rid="article-140076.r31">[31]</xref> ICGA is useful here because it directly evaluates the choroid and the RPE, which are the two most affected locations in the early course of VKH. The wavelengths used in indocyanine green angiography penetrate effectively into the choroid with reduced interference by RPE compared to fluorescein angiography.<xref ref-type="bibr" rid="article-140076.r32">[32]</xref>&#x000a0;Studies of ICGA show a 90&#x000a0;to 100% sensitivity in diagnosing VKH.<xref ref-type="bibr" rid="article-140076.r27">[27]</xref><xref ref-type="bibr" rid="article-140076.r31">[31]</xref><xref ref-type="bibr" rid="article-140076.r33">[33]</xref>&#x000a0;</p>
        <p>During the acute uveitic phase of VKH, ICGA shows focal areas of delayed choroidal perfusion, peripapillary hypercyanescence, late multifocal pinpoint leakage, and pooling in areas of serous retinal detachment.<xref ref-type="bibr" rid="article-140076.r27">[27]</xref><xref ref-type="bibr" rid="article-140076.r28">[28]</xref></p>
        <p>Optical coherence tomography (OCT) is a less invasive technique and has been utilized to study VKH and as a diagnostic tool. However, ICG angiography appears to be superior to OCT in the monitoring of chronic disease and changes.<xref ref-type="bibr" rid="article-140076.r28">[28]</xref> OCT in VKH can show septated subretinal fluid and changes in choroidal volume and thickness. OCT is an important diagnostic modality for use in multi-modal imaging to establish the diagnosis of VKH.<xref ref-type="bibr" rid="article-140076.r34">[34]</xref><xref ref-type="bibr" rid="article-140076.r35">[35]</xref>&#x000a0;Patients with recurrent VKH can show decreases in choroidal volume, as opposed to choroidal thickness, in patients even without other inflammatory signs on clinical slit-lamp examination.<xref ref-type="bibr" rid="article-140076.r36">[36]</xref><xref ref-type="bibr" rid="article-140076.r37">[37]</xref><xref ref-type="bibr" rid="article-140076.r38">[38]</xref>&#x000a0;</p>
        <p>Newer technologies like OCT-angiography (OCTA) are being evaluated for their usefulness in diagnosing and managing VKH. OCTA reveals flow void in the choriocapillaris, indicating decreased perfusion, and have been shown to correlate with the pinpoint hypercyanescence noted on ICGA. Additionally, studies of OCTA after initiation of treatment have shown a reduction in the flow void. Further study is needed to establish the role of OCTA in the management of VKH.<xref ref-type="bibr" rid="article-140076.r39">[39]</xref><xref ref-type="bibr" rid="article-140076.r40">[40]</xref></p>
      </sec>
      <sec id="article-140076.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>For many years, the treatment for VKH was intravenous pulse corticosteroid therapy. Studies indicated that the duration of therapy was linked to the risk of recurrence and further complications from repeat inflammatory episodes. Recurrence in older studies was relatively frequent and occurred within six months of treatment.<xref ref-type="bibr" rid="article-140076.r4">[4]</xref> In recent studies, patients have had significantly improved outcomes with local therapy and immunomodulatory therapy (IMT).</p>
        <p>Su-Tenon injection of triamcinolone is highly effective in leading to resolution without recurrence of ocular symptoms in up to 78% of patients, as exhibited in a study that followed patients for up to 3 years.<xref ref-type="bibr" rid="article-140076.r41">[41]</xref>&#x000a0;Fluocinolone intravitreal implant is associated with a significant decrease in recurrence rates of ocular inflammation in implanted eyes compared to nonimplanted eyes over three years.<xref ref-type="bibr" rid="article-140076.r42">[42]</xref> Both studies showed an increase in the side effect profile expected with glucocorticoid therapy, including increased risks of posterior subcapsular cataracts requiring surgical removal and intraocular pressure (IOP) increases that had a higher risk of requiring surgery. Intraocular pressure spikes occurred in intravitreal implantation both immediately post-insertion and due to steroid response. Additionally, VKH is a systemic disease, and local treatment of ocular pathology does not modulate integumentary and auditory symptoms of the disease. Therefore, monotherapy sub-tenon injection of steroids is ideal, specifically for patients already on systemic Immunomodulatory therapy (IMT) or who have minimal systemic symptoms of their disease.<xref ref-type="bibr" rid="article-140076.r42">[42]</xref><xref ref-type="bibr" rid="article-140076.r43">[43]</xref></p>
        <p>IMT has been utilized as an adjunct to steroids in patients with VKH. IMTs that have shown efficacy include alkylating agents, antimetabolites, and TNF-alpha inhibitors, among others.<xref ref-type="bibr" rid="article-140076.r44">[44]</xref><xref ref-type="bibr" rid="article-140076.r45">[45]</xref><xref ref-type="bibr" rid="article-140076.r46">[46]</xref><xref ref-type="bibr" rid="article-140076.r47">[47]</xref>&#x000a0;No specific agent has shown superiority in all cases of VKH, but cyclosporine has shown improved efficacy in cases of chronic uveitic VKH. Methotrexate has shown good efficacy in studies combining methotrexate with fluocinolone intravitreal implants, while and infliximab shows promise in pediatric populations.<xref ref-type="bibr" rid="article-140076.r48">[48]</xref><xref ref-type="bibr" rid="article-140076.r49">[49]</xref></p>
        <p>Adalimumab has most recently been studied in recalcitrant cases of patients with corticosteroid-related complications and challenging pediatric cases. It has been shown good efficacy in controlling systemic disease with evidence of complete control of inflammation for at least six months in small case studies.<xref ref-type="bibr" rid="article-140076.r50">[50]</xref><xref ref-type="bibr" rid="article-140076.r51">[51]</xref><xref ref-type="bibr" rid="article-140076.r52">[52]</xref>&#x000a0;Up to 88% of patients have been shown to achieve corticosteroid-sparing treatment of inflammation, including resolution of serous retinal detachments at baseline.<xref ref-type="bibr" rid="article-140076.r53">[53]</xref><xref ref-type="bibr" rid="article-140076.r54">[54]</xref></p>
        <p>The role of surgery is limited to treating the complications of the disease, such as cataract extraction, surgical therapy to lower the IOP or the treatment of subsequent macular holes.<xref ref-type="bibr" rid="article-140076.r55">[55]</xref><xref ref-type="bibr" rid="article-140076.r56">[56]</xref></p>
      </sec>
      <sec id="article-140076.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Sympathetic Ophthalmia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sympathetic ophthalmia is an autoimmune condition that is a direct response of penetrating trauma or surgery to the eye, exposing ocular molecules as antigenic material leading to the immune system developing an inflammatory response to the uvea. This condition also leads to bilateral non-necrotizing granulomatous uveitis.<xref ref-type="bibr" rid="article-140076.r57">[57]</xref></p>
          </list-item>
        </list>
        <p>
<bold>VKH-like Medication Toxicity (checkpoint inhibitors)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Checkpoint inhibitors have been shown to cause &#x0201c;VKH-like&#x0201d; medication toxicity that resolves with discontinuation of the inciting medications.<xref ref-type="bibr" rid="article-140076.r58">[58]</xref><xref ref-type="bibr" rid="article-140076.r59">[59]</xref><xref ref-type="bibr" rid="article-140076.r60">[60]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Choroidal Melanoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with choroidal melanoma may develop serous retinal detachments, and non-pigmented melanomas may appear as subretinal pigmentary loss similar to VKH.<xref ref-type="bibr" rid="article-140076.r57">[57]</xref><xref ref-type="bibr" rid="article-140076.r61">[61]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Infectious Posterior Uveitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Syphilis, tuberculosis, and endogenous endophthalmitis can present with subretinal nodules, intraocular inflammation, and serous retinal detachment.<xref ref-type="bibr" rid="article-140076.r62">[62]</xref><xref ref-type="bibr" rid="article-140076.r63">[63]</xref>&#x000a0;It is important to rule out infectious etiologies before starting immunosuppressive therapy.</p>
          </list-item>
        </list>
        <p>
<bold>Alport and Cogan Syndromes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Both Alport syndrome and Cogan syndrome can exhibit bilateral hearing deficits and retinal manifestations. Alport syndrome shows choroidal thickening but is characterized by significant inner retinal changes. Cogan syndrome is characterized by retinal vasculitis rather than subretinal changes.<xref ref-type="bibr" rid="article-140076.r64">[64]</xref><xref ref-type="bibr" rid="article-140076.r65">[65]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Sarcoidosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis is a distinct cause of posterior uveitis and can have multiple presentations. Periphlebitis and &#x0201c;candle-wax drippings&#x0201d; on fluorescein angiogram can help differentiate sarcoidosis from VKH.<xref ref-type="bibr" rid="article-140076.r66">[66]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Systemic Lupus Erythematosus Chorioretinopathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serous retinal detachments may be seen in lupus choroidopathy, but patients with lupus choroidopathy do not typically show choroidal thickening and often have significant systemic manifestations of their disease.<xref ref-type="bibr" rid="article-140076.r67">[67]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140076.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>There is significant interest in preparing disease-specific drugs and therapy that can reduce medication toxicity and undesirable side effects. microRNA research has presented a possible disease-specific mechanism and is currently undergoing research for clinical use in VKH.<xref ref-type="bibr" rid="article-140076.r9">[9]</xref> IFN-gamma and IL-6 have been identified as targets for future therapy.<xref ref-type="bibr" rid="article-140076.r68">[68]</xref></p>
      </sec>
      <sec id="article-140076.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>VKH may have a relatively positive prognosis if treated early and effectively. There is a cumulative worsening of prognosis with recurrent bouts of disease.<xref ref-type="bibr" rid="article-140076.r69">[69]</xref> Poor prognostic indicators include the age of patients at disease onset and the number of recurrent episodes.&#x000a0;Sunset glow fundus, a marker of the most severe stage of VKH disease and indicative of poor visual function, has been shown to occur even with control of the obvious clinical findings of the earlier stages of the disease.<xref ref-type="bibr" rid="article-140076.r69">[69]</xref>&#x000a0;</p>
        <p>Comparative studies show that treatment with both corticosteroid and supplementary IMT is necessary, decreasing the rate of sunset glow fundus from 60% in patients with VKH disease to 16%.<xref ref-type="bibr" rid="article-140076.r20">[20]</xref> Furthermore, rates of subretinal fibrosis development, an untreatable complication that can lead to permanent vision loss, were reduced in acute early patients treated with combination steroid and IMT at presentation from 34% to 16%.<xref ref-type="bibr" rid="article-140076.r2">[2]</xref><xref ref-type="bibr" rid="article-140076.r70">[70]</xref></p>
      </sec>
      <sec id="article-140076.s13" sec-type="Complications">
        <title>Complications</title>
        <p>VKH is a systemic disease, and complications of the disease include hearing loss, dysacusis, tinnitus, aural fullness, vitiligo, vertigo, and ophthalmic complications.<xref ref-type="bibr" rid="article-140076.r71">[71]</xref><xref ref-type="bibr" rid="article-140076.r72">[72]</xref>&#x000a0;Sensorineural hearing loss (SNHL) is common in VKH, affecting up to 68% of patients, but most patients who develop SNHL with VKH will recover after appropriate therapy with corticosteroids.<xref ref-type="bibr" rid="article-140076.r73">[73]</xref><xref ref-type="bibr" rid="article-140076.r74">[74]</xref><xref ref-type="bibr" rid="article-140076.r75">[75]</xref>&#x000a0;Immunomodulatory therapy is effective, but some reports show no improvement in patients who received IMT following the inability to tolerate corticosteroids.<xref ref-type="bibr" rid="article-140076.r75">[75]</xref><xref ref-type="bibr" rid="article-140076.r76">[76]</xref><xref ref-type="bibr" rid="article-140076.r77">[77]</xref>&#x000a0;Hearing loss has been shown to reverse with IMT, but cochlear implants are still frequently needed.<xref ref-type="bibr" rid="article-140076.r75">[75]</xref><xref ref-type="bibr" rid="article-140076.r78">[78]</xref><xref ref-type="bibr" rid="article-140076.r79">[79]</xref>&#x000a0;Further, patients who cannot tolerate systemic corticosteroids have shown improvement in auditory symptoms with intratympanic corticosteroid injection. (22180111) Vertigo is less common in patients with VKH (17-19%) and can cause significant morbidity; this symptom responds well to steroid therapy.<xref ref-type="bibr" rid="article-140076.r72">[72]</xref><xref ref-type="bibr" rid="article-140076.r75">[75]</xref><xref ref-type="bibr" rid="article-140076.r80">[80]</xref></p>
        <p>The most common integumentary symptoms of VKH are poliosis and vitiligo. Poliosis and vitiligo have been shown to slow and respond well to systemic treatment with corticosteroids and IMT. Further, topical treatment with calcineurin inhibitors and corticosteroids has shown reversal of depigmented areas of skin.<xref ref-type="bibr" rid="article-140076.r81">[81]</xref></p>
        <p>In the acute uveitic phase of the disease, VKH can lead to ciliary body inflammation and edema with subsequent closure of the anterior segment angle leading to acute angle-closure glaucoma.<xref ref-type="bibr" rid="article-140076.r28">[28]</xref><xref ref-type="bibr" rid="article-140076.r82">[82]</xref>&#x000a0;In these patients, IOP is elevated, with a median IOP of 32.9 (range 27-40), and treatment of the intraocular pressure with IOP-lowering therapy is usually ineffective. Case series of these patients show that cycloplegic agents and laser peripheral iridotomies do not improve the intraocular pressure during angle closure. To our knowledge, there is no study regarding the treatment of patients with VKH utilizing glaucoma drainage implants. Patients with ciliary body edema secondary to inflammation in VKH show transient IOP lowering using acetazolamide. Treatment of inflammation is likely the most important aspect of IOP management.<xref ref-type="bibr" rid="article-140076.r82">[82]</xref><xref ref-type="bibr" rid="article-140076.r83">[83]</xref></p>
        <p>Visually significant ophthalmic complications of chronic VKH include cataracts, glaucoma, neovascular glaucoma, macular holes, chronic retinal detachments, subretinal fibrosis, and choroidal neovascularization.<xref ref-type="bibr" rid="article-140076.r84">[84]</xref><xref ref-type="bibr" rid="article-140076.r85">[85]</xref><xref ref-type="bibr" rid="article-140076.r86">[86]</xref><xref ref-type="bibr" rid="article-140076.r87">[87]</xref>&#x000a0;Cataracts occur in up to 45% of patients and result from intraocular inflammation and corticosteroid therapy, leading to posterior subcapsular cataracts. Once patients achieve inflammatory control for three months as recommended by the criteria set forward by van Gelder, patients generally do well with cataract surgery, with significant visual improvement in 99% of eyes.<xref ref-type="bibr" rid="article-140076.r88">[88]</xref><xref ref-type="bibr" rid="article-140076.r89">[89]</xref><xref ref-type="bibr" rid="article-140076.r90">[90]</xref>&#x000a0;</p>
        <p>One study noted a desirable postoperative outcome with one month of inflammation control with IMT and corticosteroids.&#x000a0;Notably, up to 10% of eyes can develop hyphema postoperatively, and ocular hypertension occurs in up to 13% of eyes postoperatively, but both conditions resolve spontaneously. Consistent with an intraocular inflammatory condition, up to 50% of patients with VKH develop posterior capsular opacification after phacoemulsification.<xref ref-type="bibr" rid="article-140076.r91">[91]</xref><xref ref-type="bibr" rid="article-140076.r89">[89]</xref></p>
        <p>Ocular hypertension and glaucomatous optic neuropathy are common in patients with VKH. Up to 33% of patients with VKH will develop ocular hypertension. Significant risks for the development of ocular hypertension include poor visual acuity at initial presentation, time from symptoms to treatment, and the number of recurrent episodes of disease. Glaucoma develops in 16&#x000a0;to 18% of patients, and the primary cause of glaucoma in these patients is open-angle and not steroid-induced, but a significant percent of VKH patients who develop glaucoma developed glaucomatous optic neuropathy from pupillary block secondary to posterior synechiae.<xref ref-type="bibr" rid="article-140076.r92">[92]</xref></p>
        <p>Chronic serous retinal detachments leading to subretinal fibrosis are a significant cause of severe vision loss. Subretinal fibrosis occurs in 6% of eyes with VKH. Still, it has been shown to occur much earlier in Hispanic patients &#x02013; roughly six months in Hispanic patients compared to 6 years in non-Hispanic patients. Subretinal fibrosis appears to be much more common in the Western Hemisphere, with rates as high as 6%, whereas studies in southern and eastern Asia have very few cases.<xref ref-type="bibr" rid="article-140076.r93">[93]</xref><xref ref-type="bibr" rid="article-140076.r94">[94]</xref><xref ref-type="bibr" rid="article-140076.r95">[95]</xref><xref ref-type="bibr" rid="article-140076.r96">[96]</xref>&#x000a0;</p>
        <p>Subretinal fibrosis is also a poor prognostic indicator, with numerous studies showing worsening even with combined corticosteroid and IMT therapy. However, one study showed favorable outcomes with combination mycophenolate mofetil and systemic corticosteroids.<xref ref-type="bibr" rid="article-140076.r84">[84]</xref><xref ref-type="bibr" rid="article-140076.r85">[85]</xref>&#x000a0;Subretinal fibrosis can lead to macular detachments, which can severely compromise vision. These specific macular detachments can be treated surgically with pars plana vitrectomy and vitreous tamponade.<xref ref-type="bibr" rid="article-140076.r97">[97]</xref></p>
        <p>Choroidal neovascular membranes have been shown to occur in 14 to 17% of patients with VKH and are responsive to anti-VEGF therapy.<xref ref-type="bibr" rid="article-140076.r98">[98]</xref><xref ref-type="bibr" rid="article-140076.r99">[99]</xref></p>
      </sec>
      <sec id="article-140076.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>It is paramount that patients with VKH receive appropriate referrals to manage integumentary and auditory manifestations of the disease. Audiology, otorhinolaryngology, and dermatology referrals should be promptly initiated further to monitor the course of the patient&#x02019;s disease.</p>
      </sec>
      <sec id="article-140076.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>It is important to reinforce to patients that Vogt-Koyanagi-Harada disease is a systemic disease and one that can relapse and recur. Untreated recurrent episodes of the disease lead to progressively worse outcomes, and patients often require lifelong immunosuppressive therapy. Patients should be educated on the various manifestations of the disease to recognize when their condition is relapsing.</p>
      </sec>
      <sec id="article-140076.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Although rare, VKH must be considered in cases of eye pain and associated headache and/or meningeal signs.</p>
        <p>The therapy goals are not only to reduce clinically apparent disease but also to decrease the progression of the complications of VKH disease through proper identification and early treatment.</p>
        <p>Corticosteroids have an established role in treating VKH, but data show increased recurrence and complications when used as monotherapy and without IMT.</p>
      </sec>
      <sec id="article-140076.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>VKH, when caught early, can be effectively managed and treated by the appropriate specialties as part of a care team that includes primary care physicians, emergency room physicians, and specialists in low vision, otorhinolaryngology, ophthalmology, and audiology.</p>
      </sec>
      <sec id="article-140076.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140076&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140076">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/vogt-koyanagi-harada-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140076">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140076/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140076">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-140076.s19">
        <title>References</title>
        <ref id="article-140076.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbort</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.</article-title>
            <source>Int Ophthalmol</source>
            <year>2007</year>
            <season>Apr-Jun</season>
            <volume>27</volume>
            <issue>2-3</issue>
            <fpage>67</fpage>
            <page-range>67-79</page-range>
            <pub-id pub-id-type="pmid">17468832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golzarri</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Cheja-Kalb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Concha-Del-R&#x000ed;o</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Gonzalez-Salinas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arellanes-Garc&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for subretinal fibrosis in patients with Vogt Koyanagi Harada syndrome.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2022</year>
            <month>Feb</month>
            <day>17</day>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-269</page-range>
            <pub-id pub-id-type="pmid">33021860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaza</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tyagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pappuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saldanha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Videkar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pathengay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vogt Koyanagi Harada Disease In Paediatric Age Group: Clinical Characteristics, Remission, Recurrences and Complications in Asian Indian Population.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2022</year>
            <month>Feb</month>
            <day>17</day>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-192</page-range>
            <pub-id pub-id-type="pmid">34224303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubsamen</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1991</year>
            <month>May</month>
            <volume>109</volume>
            <issue>5</issue>
            <fpage>682</fpage>
            <page-range>682-7</page-range>
            <pub-id pub-id-type="pmid">2025171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mochizuki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Regional immunity of the eye.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2010</year>
            <month>May</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>292</fpage>
            <page-range>292-9</page-range>
            <pub-id pub-id-type="pmid">19900207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2016</year>
            <month>May</month>
            <volume>52</volume>
            <fpage>84</fpage>
            <page-range>84-111</page-range>
            <pub-id pub-id-type="pmid">26875727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diallo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Revuz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clavel-Refregiers</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sen&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Titah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerfaud-Valentin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jaussaud</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2020</year>
            <month>Oct</month>
            <day>07</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>395</fpage>
            <pub-id pub-id-type="pmid">33028239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albalawi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al-Barry</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Genetic variations in autoimmune genes and VKH disease.</article-title>
            <source>Int Ophthalmol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>3175</fpage>
            <page-range>3175-3186</page-range>
            <pub-id pub-id-type="pmid">32974831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vega-Tapia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bustamante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Urzua</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cuitino</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Front Cell Dev Biol</source>
            <year>2021</year>
            <volume>9</volume>
            <fpage>658514</fpage>
            <pub-id pub-id-type="pmid">34041239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohguro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sonoda</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The 2009 prospective multi-center epidemiologic survey of uveitis in Japan.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>432</fpage>
            <page-range>432-5</page-range>
            <pub-id pub-id-type="pmid">22752308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de-la-Torre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Castillo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Rueda</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mantilla</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Mar&#x000ed;n</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Anaya</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>458</fpage>
            <page-range>458-66</page-range>
            <pub-id pub-id-type="pmid">19624341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Justin</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Dahr</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease in a Native American population in Oklahoma.</article-title>
            <source>Int Ophthalmol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>915</fpage>
            <page-range>915-922</page-range>
            <pub-id pub-id-type="pmid">33403519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishikawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shiono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease in identical twins.</article-title>
            <source>Retina</source>
            <year>1994</year>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>435</fpage>
            <page-range>435-7</page-range>
            <pub-id pub-id-type="pmid">7899719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rutzen</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ortega-Larrocea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Simultaneous onset of Vogt-Koyanagi-Harada syndrome in monozygotic twins.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-40</page-range>
            <pub-id pub-id-type="pmid">7832237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Itho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kouno</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease in monozygotic twins.</article-title>
            <source>Int Ophthalmol</source>
            <year>1992</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-54</page-range>
            <pub-id pub-id-type="pmid">1537650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beniz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forster</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lean</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Variations in clinical features of the Vogt-Koyanagi-Harada syndrome.</article-title>
            <source>Retina</source>
            <year>1991</year>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-80</page-range>
            <pub-id pub-id-type="pmid">1961985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiyomoto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Imaizumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakatsuka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease in elderly Japanese patients.</article-title>
            <source>Int Ophthalmol</source>
            <year>2007</year>
            <season>Apr-Jun</season>
            <volume>27</volume>
            <issue>2-3</issue>
            <fpage>149</fpage>
            <page-range>149-53</page-range>
            <pub-id pub-id-type="pmid">17437061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabbara</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Chavis</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada syndrome in children compared to adults.</article-title>
            <source>Acta Ophthalmol Scand</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>723</fpage>
            <page-range>723-6</page-range>
            <pub-id pub-id-type="pmid">9881561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albaroudi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tijani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boutimzine</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cherkaoui</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Clinical and therapeutic features of pediatric Vogt-Koyanagi-Harada disease.</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2020</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>427</fpage>
            <page-range>427-432</page-range>
            <pub-id pub-id-type="pmid">32115269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>AlBloushi</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>AlEnezi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Al Owaifeer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al-Hadlaq</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Gikandi</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Abu El-Asrar</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Long-term Outcomes of Uveitis Associated with Vogt-Koyanagi-Harada Disease in the Pediatric Age Group.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2022</year>
            <season>Oct-Nov</season>
            <volume>30</volume>
            <issue>7-8</issue>
            <fpage>1669</fpage>
            <page-range>1669-1677</page-range>
            <pub-id pub-id-type="pmid">34184966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takase</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kawaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease.</article-title>
            <source>Int Ophthalmol</source>
            <year>2007</year>
            <season>Apr-Jun</season>
            <volume>27</volume>
            <issue>2-3</issue>
            <fpage>87</fpage>
            <page-range>87-95</page-range>
            <pub-id pub-id-type="pmid">17253112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prignano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Betts</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin?</article-title>
            <source>J Electron Microsc (Tokyo)</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-31</page-range>
            <pub-id pub-id-type="pmid">18174263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minoda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Osato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[High inducibility of Epstein-Barr virus replication in B lymphocytes in Vogt-Koyanagi-Harada disease].</article-title>
            <source>Nippon Ganka Gakkai Zasshi</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-96</page-range>
            <pub-id pub-id-type="pmid">10339973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Keefe</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-25</page-range>
            <pub-id pub-id-type="pmid">27241814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <collab>Standardization of Uveitis Nomenclature (SUN) Working Group</collab>
            <article-title>Classification Criteria for Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>228</volume>
            <fpage>205</fpage>
            <page-range>205-211</page-range>
            <pub-id pub-id-type="pmid">33845018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YZ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XL</given-names>
              </name>
            </person-group>
            <article-title>Melanin change of retinal pigment epithelium and choroid in the convalescent stage of Vogt-Koyanagi-Harada disease.</article-title>
            <source>Int J Ophthalmol</source>
            <year>2020</year>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>1928</fpage>
            <page-range>1928-1932</page-range>
            <pub-id pub-id-type="pmid">33344192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Development and Evaluation of Diagnostic Criteria for Vogt-Koyanagi-Harada Disease.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>136</volume>
            <issue>9</issue>
            <fpage>1025</fpage>
            <page-range>1025-1031</page-range>
            <pub-id pub-id-type="pmid">29978190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbort</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Tugal-Tutkun</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Abu-El-Asrar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fardeau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hedayatfar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Urzua</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Papasavvas</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.</article-title>
            <source>Eye (Lond)</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-43</page-range>
            <pub-id pub-id-type="pmid">34145419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sultan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Abdulsalam</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Dec</month>
            <day>29</day>
            <volume>12</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">31888891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Elevated Serum Immunoglobulin E Levels are Associated with the Severity of Newly Diagnosed, Acute Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Curr Eye Res</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-106</page-range>
            <pub-id pub-id-type="pmid">34264155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ham</surname>
                <given-names>DI</given-names>
              </name>
            </person-group>
            <article-title>Ultra-wide-field angiography findings in acute Vogt-Koyanagi-Harada disease.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>103</volume>
            <issue>7</issue>
            <fpage>942</fpage>
            <page-range>942-948</page-range>
            <pub-id pub-id-type="pmid">30100554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yannuzzi</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Indocyanine green angiography: a perspective on use in the clinical setting.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2011</year>
            <month>May</month>
            <volume>151</volume>
            <issue>5</issue>
            <fpage>745</fpage>
            <page-range>745-751.e1</page-range>
            <pub-id pub-id-type="pmid">21501704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balci</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jeannin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Herbort</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease.</article-title>
            <source>Int Ophthalmol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>527</fpage>
            <page-range>527-539</page-range>
            <pub-id pub-id-type="pmid">28299496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography.</article-title>
            <source>Eye (Lond)</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>1993</fpage>
            <page-range>1993-1998</page-range>
            <pub-id pub-id-type="pmid">33024324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugitani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kurobe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirahara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yasukawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Three-dimensional analysis of choroidal vessels in eyes with Vogt-Koyanagi-Harada disease before and after treatment.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>500</fpage>
            <page-range>500-508</page-range>
            <pub-id pub-id-type="pmid">32835675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Azad</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Delayed-onset unilateral Vogt-Koyanagi-Harada syndrome: a multimodal imaging appraisal.</article-title>
            <source>BMJ Case Rep</source>
            <year>2021</year>
            <month>Feb</month>
            <day>10</day>
            <volume>14</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33568408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Retinal Microcirculation Defects on OCTA Correlate with Active Inflammation and Vision in Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2021</year>
            <month>Nov</month>
            <day>17</day>
            <volume>29</volume>
            <issue>7-8</issue>
            <fpage>1417</fpage>
            <page-range>1417-1423</page-range>
            <pub-id pub-id-type="pmid">32407159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Autofluorescence combined with spectral domain optical coherence tomography for diagnosis and follow-up of acute Vogt-Koyanagi-Harada disease].</article-title>
            <source>Nan Fang Yi Ke Da Xue Xue Bao</source>
            <year>2021</year>
            <month>Jan</month>
            <day>30</day>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <page-range>135-140</page-range>
            <pub-id pub-id-type="pmid">33509766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Govetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scialdone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casalino</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Role of optical coherence tomography angiography in Vogt-Koyanagi-Harada disease.</article-title>
            <source>GMS Ophthalmol Cases</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>Doc06</fpage>
            <pub-id pub-id-type="pmid">33796433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aggarwal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mandadi</surname>
                <given-names>SKR</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dogra</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <collab>OCTA Study Group</collab>
            </person-group>
            <article-title>The Role of Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2018</year>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>142</fpage>
            <page-range>142-153</page-range>
            <pub-id pub-id-type="pmid">27440118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuriyama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Posterior subtenon triamcinolone acetonide injection as a primary treatment in eyes with acute Vogt-Koyanagi-Harada disease.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>99</volume>
            <issue>9</issue>
            <fpage>1211</fpage>
            <page-range>1211-4</page-range>
            <pub-id pub-id-type="pmid">25792626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heo</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sepah</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
            </person-group>
            <article-title>FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety.</article-title>
            <source>Retina</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>2124</fpage>
            <page-range>2124-2131</page-range>
            <pub-id pub-id-type="pmid">27333235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urzua</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Velasquez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sabat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goecke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>V&#x000e1;squez</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Gatica</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guerrero</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>93</volume>
            <issue>6</issue>
            <fpage>e475</fpage>
            <page-range>e475-80</page-range>
            <pub-id pub-id-type="pmid">25565265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolletta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gozzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mastrofilippo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pipitone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>De Simone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Croci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iannetta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coassin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cimino</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>1303</fpage>
            <page-range>1303-1308</page-range>
            <pub-id pub-id-type="pmid">33793383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu El-Asrar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hemachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Mezaine</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kangave</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Al-Muammar</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>90</volume>
            <issue>8</issue>
            <fpage>e603</fpage>
            <page-range>e603-8</page-range>
            <pub-id pub-id-type="pmid">22971163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Concha-Del R&#x000ed;o</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Arellanes-Garc&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Arch Soc Esp Oftalmol (Engl Ed)</source>
            <year>2018</year>
            <month>May</month>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>225</fpage>
            <page-range>225-230</page-range>
            <pub-id pub-id-type="pmid">29258782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu El-Asrar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dosari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hemachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gikandi</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Al-Muammar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-90</page-range>
            <pub-id pub-id-type="pmid">27535102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>VB</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis.</article-title>
            <source>Am J Ophthalmol Case Rep</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>19</volume>
            <fpage>100859</fpage>
            <pub-id pub-id-type="pmid">32793845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budmann</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Pringe</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease.</article-title>
            <source>Am J Ophthalmol Case Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>11</volume>
            <fpage>139</fpage>
            <page-range>139-141</page-range>
            <pub-id pub-id-type="pmid">29998211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takayama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Obata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2020</year>
            <month>Apr</month>
            <day>02</day>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>509</fpage>
            <page-range>509-512</page-range>
            <pub-id pub-id-type="pmid">31268769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oza</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Latkany</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab.</article-title>
            <source>J Formos Med Assoc</source>
            <year>2019</year>
            <month>May</month>
            <volume>118</volume>
            <issue>5</issue>
            <fpage>945</fpage>
            <page-range>945-950</page-range>
            <pub-id pub-id-type="pmid">30616991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Couto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schlaen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hurtado</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2018</year>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>485</fpage>
            <page-range>485-489</page-range>
            <pub-id pub-id-type="pmid">27775450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rathinam</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanakath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thundikandy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Browne</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Porco</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>168</volume>
            <fpage>279</fpage>
            <page-range>279-286</page-range>
            <pub-id pub-id-type="pmid">27296490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Errera</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fardeau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaudric</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Westcott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LeHoang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>e357</fpage>
            <page-range>e357-66</page-range>
            <pub-id pub-id-type="pmid">21251241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arcinue</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Radwan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lebanan</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2013</year>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-52</page-range>
            <pub-id pub-id-type="pmid">23323581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rathinam</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thundikandy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kanakath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nardone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Esterberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Enanoria</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Porco</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Browne</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Weinrib</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>121</volume>
            <issue>10</issue>
            <fpage>1863</fpage>
            <page-range>1863-70</page-range>
            <pub-id pub-id-type="pmid">24917273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rishi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Appanraj</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Choroidal melanoma masquerading as multifocal central serous chorioretinopathy.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2016</year>
            <season>Sep-Dec</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-188</page-range>
            <pub-id pub-id-type="pmid">27843240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ushio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyasaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muraoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanaoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Izawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hirama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Teranishi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.</article-title>
            <source>Intern Med</source>
            <year>2021</year>
            <month>Nov</month>
            <day>15</day>
            <volume>60</volume>
            <issue>22</issue>
            <fpage>3593</fpage>
            <page-range>3593-3598</page-range>
            <pub-id pub-id-type="pmid">34092725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gambichler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lukas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scheel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Susok</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.</article-title>
            <source>Immunotherapy</source>
            <year>2020</year>
            <month>May</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>439</fpage>
            <page-range>439-444</page-range>
            <pub-id pub-id-type="pmid">32308086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diamantopoulos</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Stoungioti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anastasopoulou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papaxoinis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gogas</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.</article-title>
            <source>Melanoma Res</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>648</fpage>
            <page-range>648-651</page-range>
            <pub-id pub-id-type="pmid">30169430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Di Nicola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucio-Alvarez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lally</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Choroidal Melanoma Simulating Adenoma of the Retinal Pigment Epithelium Arising at the Site of Congenital Hypertrophy of the Retinal Pigment Epithelium.</article-title>
            <source>Ocul Oncol Pathol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-43</page-range>
            <pub-id pub-id-type="pmid">32002404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwata</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mizuuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kase</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Namba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kitaichi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Serial Frequencies and Clinical Features of Uveitis in Hokkaido, Japan.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2017</year>
            <volume>25</volume>
            <issue>sup1</issue>
            <fpage>S15</fpage>
            <page-range>S15-S18</page-range>
            <pub-id pub-id-type="pmid">27438588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez Fernandez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Muccioli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Belfort</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Uveitis in S&#x000e3;o Paulo, Brazil: 1053 New Patients in 15 Months.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-387</page-range>
            <pub-id pub-id-type="pmid">26914347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trancoso</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Gallon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bomfim</surname>
                <given-names>MLA</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>AFMD</given-names>
              </name>
              <name>
                <surname>Cade</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zanetti</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography angiography findings in patients with Alport syndrome.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2020</year>
            <season>Nov-Dec</season>
            <volume>83</volume>
            <issue>6</issue>
            <fpage>473</fpage>
            <page-range>473-477</page-range>
            <pub-id pub-id-type="pmid">33470273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhandari</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Duggal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cogan syndrome: An autoimmune eye and ear disease with systemic manifestations.</article-title>
            <source>Natl Med J India</source>
            <year>2019</year>
            <season>Nov-Dec</season>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>349</fpage>
            <page-range>349-351</page-range>
            <pub-id pub-id-type="pmid">33380629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dammacco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kivel&#x000e4;</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Zito</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mavilio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sisto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alessio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dammacco</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements.</article-title>
            <source>Int Ophthalmol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>3453</fpage>
            <page-range>3453-3467</page-range>
            <pub-id pub-id-type="pmid">32740881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghem</surname>
                <given-names>MRD</given-names>
              </name>
              <name>
                <surname>Hungaro</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hokazono</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Serous retinal detachment as an Early manifestation of l&#x000fa;pus choroidopathy.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>84</volume>
            <issue>6</issue>
            <fpage>594</fpage>
            <page-range>594-597</page-range>
            <pub-id pub-id-type="pmid">34431880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Integrated Analysis of Key Pathways and Drug Targets Associated With Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Front Immunol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>587443</fpage>
            <pub-id pub-id-type="pmid">33384687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arevalo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lasave</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kozak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Al Harbi</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Al Rushood</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Al Dhibi</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>521</fpage>
            <page-range>521-9</page-range>
            <pub-id pub-id-type="pmid">26399962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakata</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Marin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kalil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2015</year>
            <month>May</month>
            <volume>253</volume>
            <issue>5</issue>
            <fpage>785</fpage>
            <page-range>785-90</page-range>
            <pub-id pub-id-type="pmid">25592477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>AlHelali</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hajr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Almuhawas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hagr</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bilateral Cochlear Implantation in Vogt-Koyanagi-Harada Syndrome: A Case Report.</article-title>
            <source>Otol Neurotol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>e694</fpage>
            <page-range>e694-e697</page-range>
            <pub-id pub-id-type="pmid">31219962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ondrey</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Moldestad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mastroianni</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pikus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sklare</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nusenblatt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sensorineural hearing loss in Vogt-Koyanagi-Harada syndrome.</article-title>
            <source>Laryngoscope</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>116</volume>
            <issue>10</issue>
            <fpage>1873</fpage>
            <page-range>1873-6</page-range>
            <pub-id pub-id-type="pmid">17003710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takase</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miyanaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Audiovestibular findings in patients with Vogt-Koyanagi-Harada disease.</article-title>
            <source>Acta Otolaryngol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>134</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-44</page-range>
            <pub-id pub-id-type="pmid">24628333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chatrath</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gatland</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Deafness in Vogt-Koyanagi-Harada syndrome.</article-title>
            <source>J Laryngol Otol</source>
            <year>2006</year>
            <month>May</month>
            <volume>120</volume>
            <issue>5</issue>
            <fpage>416</fpage>
            <page-range>416-8</page-range>
            <pub-id pub-id-type="pmid">16696884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Dousary</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Auditory and vestibular manifestations of Vogt-Koyanagi-Harada disease.</article-title>
            <source>J Laryngol Otol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>125</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-41</page-range>
            <pub-id pub-id-type="pmid">20880417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wakatsuki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kogure</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oguro</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with cyclosporin A and steroid in severe case of Vogt-Koyanagi-Harada's disease.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>1988</year>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>358</fpage>
            <page-range>358-60</page-range>
            <pub-id pub-id-type="pmid">3230722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Palestine</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1983</year>
            <month>Sep</month>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-82</page-range>
            <pub-id pub-id-type="pmid">6614105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rigante</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vitale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bascherini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Latronico</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Franceschini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cantarini</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.</article-title>
            <source>Clin Rheumatol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>1817</fpage>
            <page-range>1817-20</page-range>
            <pub-id pub-id-type="pmid">25224382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sydlowski</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Luffler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haberkamp</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Successful cochlear implantation in a case of Vogt-Koyanagi-Harada disease.</article-title>
            <source>Otol Neurotol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1522</fpage>
            <page-range>1522-4</page-range>
            <pub-id pub-id-type="pmid">24770410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujiwara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoshino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakamaru</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Homma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Vestibular Functions in Patients with Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Audiol Neurootol</source>
            <year>2017</year>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>190</fpage>
            <page-range>190-195</page-range>
            <pub-id pub-id-type="pmid">29080887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bayer</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>YE</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Vitiligo Associated with Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>204</fpage>
            <page-range>204-205</page-range>
            <pub-id pub-id-type="pmid">27981622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Bilateral acute angle closure glaucoma as an initial presentation of Vogt-Koyanagi-Harada syndrome: A clinical case report.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>NP230</fpage>
            <page-range>NP230-NP234</page-range>
            <pub-id pub-id-type="pmid">32811185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada disease presenting as acute angle closure glaucoma at onset.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2011</year>
            <season>Sep-Oct</season>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>639</fpage>
            <page-range>639-47</page-range>
            <pub-id pub-id-type="pmid">22452682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu El-Asrar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al Tamimi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hemachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Mezaine</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Al-Muammar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kangave</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>e486</fpage>
            <page-range>e486-93</page-range>
            <pub-id pub-id-type="pmid">23575246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paredes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>87</fpage>
            <page-range>87-90</page-range>
            <pub-id pub-id-type="pmid">16597537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakata</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>de Carvalho</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and classification of Vogt-Koyanagi-Harada disease.</article-title>
            <source>Autoimmun Rev</source>
            <year>2014</year>
            <season>Apr-May</season>
            <volume>13</volume>
            <issue>4-5</issue>
            <fpage>550</fpage>
            <page-range>550-5</page-range>
            <pub-id pub-id-type="pmid">24440284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kryshtalskyj</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2022</year>
            <month>May</month>
            <day>19</day>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>894</fpage>
            <page-range>894-900</page-range>
            <pub-id pub-id-type="pmid">33621146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganesh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Padmaja</surname>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cataract surgery in patients with Vogt-Koyanagi-Harada syndrome.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <page-range>95-100</page-range>
            <pub-id pub-id-type="pmid">14967274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manandhar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Outcome of cataract surgery in eyes with uveitis.</article-title>
            <source>Nepal J Ophthalmol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>22</issue>
            <fpage>152</fpage>
            <page-range>152-157</page-range>
            <pub-id pub-id-type="pmid">32792691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conway</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Enfield</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Peyman</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Management of cataract in uveitis patients.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-74</page-range>
            <pub-id pub-id-type="pmid">29095715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eghrari</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Outcome and Prognostic Factors of Phacoemulsification Cataract Surgery in Vogt-Koyanagi-Harada Uveitis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>196</volume>
            <fpage>121</fpage>
            <page-range>121-128</page-range>
            <pub-id pub-id-type="pmid">30194930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, risk factors and management of ocular hypertension or glaucoma in patients with Vogt-Koyanagi-Harada disease.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>1678</fpage>
            <page-range>1678-1682</page-range>
            <pub-id pub-id-type="pmid">33011689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.</article-title>
            <source>Ophthalmology</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>114</volume>
            <issue>3</issue>
            <fpage>606</fpage>
            <page-range>606-14</page-range>
            <pub-id pub-id-type="pmid">17123618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mondkar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ganesh</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Analysis of 87 cases with Vogt-Koyanagi-Harada disease.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>2000</year>
            <season>May-Jun</season>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>296</fpage>
            <page-range>296-301</page-range>
            <pub-id pub-id-type="pmid">10913650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murthy</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Moreker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sangwan</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Tejwani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of Vogt-Koyanagi-Harada disease in South India.</article-title>
            <source>Int Ophthalmol</source>
            <year>2007</year>
            <season>Apr-Jun</season>
            <volume>27</volume>
            <issue>2-3</issue>
            <fpage>131</fpage>
            <page-range>131-6</page-range>
            <pub-id pub-id-type="pmid">17318321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chee</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Jap</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bacsal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>147</volume>
            <issue>1</issue>
            <fpage>154</fpage>
            <page-range>154-161.e1</page-range>
            <pub-id pub-id-type="pmid">18834575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Surgical Treatment of Subretinal Fibrosis Caused Macular Detachment in Vogt-Koyanagi-Harada Disease: A Pioneer Study.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2018</year>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>154</fpage>
            <page-range>154-159</page-range>
            <pub-id pub-id-type="pmid">27494778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dustin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Khairallah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lehoang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Accorinti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prabriputaloong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease.</article-title>
            <source>Ophthalmology</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>591</fpage>
            <page-range>591-9, 599.e1</page-range>
            <pub-id pub-id-type="pmid">20036008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140076.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karti</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ipek</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ates</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saatci</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory Choroidal Neovascular Membranes in Patients With Noninfectious Uveitis: The Place of Intravitreal Anti-VEGF Therapy.</article-title>
            <source>Med Hypothesis Discov Innov Ophthalmol</source>
            <year>2020</year>
            <season>Summer</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-126</page-range>
            <pub-id pub-id-type="pmid">32490018</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
